|
Dr.
Steffen Goletz, CEO, CSO and
co-founder of the biotech company GLYCOTOPE, studied biology, biochemistry
and molecular biology at the universities in Heidelberg, Kaiserslautern,
Manchester (UK) and Berlin and holds a Ph.D. in biochemistry. During his
scientific career he worked for renowned research institutions including the
Max Delbrueck Centre for Molecular Medicine (Berlin), the MRC Centre for
Protein Engineering (Cambridge, UK), and the German Cancer Research Centre
in Heidelberg. During his research, Dr. Goletz has focused on glycobiology,
tumor immunology, antibody engineering and cellular engineering. As CSO,
Steffen is responsible for the extremely successful development of
GLYCOTOPEs product pipeline of glycooptimized biotherapeutics with four
products currently in clinical trials. GLYCOTOPE developed the novel
expression platform GlycoExpress based on human glycoengineered cell lines
which is used for the generation of improved biopharmaceuticals with fully
human and optimized glycosylation.
|
